Advertisement
Screener

INOVIO PHARMACEUTICALS, INC. (INO) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

INOVIO PHARMACEUTICALS, INC. Operating Expenses

INOVIO PHARMACEUTICALS, INC. (INO) reported Operating Expenses of $18.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2026-08-12

  • INOVIO PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-06-30 was $18.62M, a 19.32% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. operating expenses for the quarter ending 2026-03-31 was $21.95M, a 12.61% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-12-31 was $17.48M, a 14.69% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. operating expenses for the quarter ending 2025-09-30 was $21.21M, a 22.44% decline year-over-year.
  • INOVIO PHARMACEUTICALS, INC. operating expenses for fiscal 2025 was $86.89M, a 22.85% decline from fiscal 2024.
  • INOVIO PHARMACEUTICALS, INC. operating expenses for fiscal 2024 was $112.62M, a 22.21% decline from fiscal 2023.
  • INOVIO PHARMACEUTICALS, INC. operating expenses for fiscal 2023 was $144.77M, a 47.89% decline from fiscal 2022.
  • INOVIO PHARMACEUTICALS, INC. operating expenses for fiscal 2022 was $277.84M, a 8.30% decline from fiscal 2021.
Period endOperating Expenses 3 monthOperating Expenses 6 monthOperating Expenses 9 monthOperating Expenses 12 month
2026-06-30$18.62M
10-Q · filed 2026-08-12
$40.57M
10-Q · filed 2026-08-12
$58.05M
derived: sum of 3 quarters · filed 2026-08-12
$79.26M
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31$21.95M
10-Q · filed 2026-05-13
$39.43M
derived: sum of 2 quarters · filed 2026-05-13
$60.64M
derived: sum of 3 quarters · filed 2026-05-13
$83.72M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$17.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$38.69M
derived: sum of 2 quarters · filed 2026-03-12
$61.77M
derived: sum of 3 quarters · filed 2026-08-12
$86.89M
10-K · filed 2026-03-12
2025-09-30$21.21M
10-Q · filed 2025-11-10
$44.29M
derived: sum of 2 quarters · filed 2026-08-12
$69.41M
10-Q · filed 2025-11-10
$89.90M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30$23.08M
10-Q · filed 2026-08-12
$48.20M
10-Q · filed 2026-08-12
$68.69M
derived: sum of 3 quarters · filed 2026-08-12
$96.03M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31$25.12M
10-Q · filed 2026-05-13
$45.60M
derived: sum of 2 quarters · filed 2026-05-13
$72.95M
derived: sum of 3 quarters · filed 2026-05-13
$106.25M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$20.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12
$47.83M
derived: sum of 2 quarters · filed 2026-03-12
$81.13M
derived: sum of 3 quarters · filed 2026-03-12
$112.62M
10-K · filed 2026-03-12
2024-09-30$27.35M
10-Q · filed 2025-11-10
$60.65M
derived: sum of 2 quarters · filed 2025-11-10
$92.13M
10-Q · filed 2025-11-10
$119.63M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30$33.30M
10-Q · filed 2025-08-12
$64.78M
10-Q · filed 2025-08-12
$92.28M
derived: sum of 3 quarters · filed 2025-08-12
$128.22M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$31.48M
10-Q · filed 2025-05-13
$58.98M
derived: sum of 2 quarters · filed 2025-05-13
$94.92M
derived: sum of 3 quarters · filed 2025-05-13
$132.19M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$27.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18
$63.44M
derived: sum of 2 quarters · filed 2025-03-18
$100.70M
derived: sum of 3 quarters · filed 2025-03-18
$144.77M
10-K · filed 2025-03-18
2023-09-30$35.94M
10-Q · filed 2024-11-14
$73.21M
derived: sum of 2 quarters · filed 2024-11-14
$117.28M
10-Q · filed 2024-11-14
$173.35M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$37.27M
10-Q · filed 2024-08-08
$81.33M
10-Q · filed 2024-08-08
$137.41M
derived: sum of 3 quarters · filed 2024-08-08
$182.32M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$44.07M
10-Q · filed 2024-05-13
$100.14M
derived: sum of 2 quarters · filed 2024-05-13
$145.05M
derived: sum of 3 quarters · filed 2024-05-13
$249.97M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31$56.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06
$100.98M
derived: sum of 2 quarters · filed 2024-03-06
$205.90M
derived: sum of 3 quarters · filed 2024-03-06
$277.84M
10-K · filed 2024-03-06
2022-09-30$44.91M
10-Q · filed 2023-11-09
$149.83M
derived: sum of 2 quarters · filed 2023-11-09
$221.76M
10-Q · filed 2023-11-09
$328.11M
derived: sum of 4 quarters · filed 2024-03-06
2022-06-30$104.92M
10-Q · filed 2023-08-09
$176.85M
10-Q · filed 2023-08-09
$283.20M
derived: sum of 3 quarters · filed 2024-03-06
$343.45M
derived: sum of 4 quarters · filed 2024-03-06
2022-03-31$71.93M
10-Q · filed 2023-05-10
$178.28M
derived: sum of 2 quarters · filed 2024-03-06
$238.52M
derived: sum of 3 quarters · filed 2024-03-06
$322.00M
derived: sum of 4 quarters · filed 2024-03-06
2021-12-31$106.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06
$166.59M
derived: sum of 2 quarters · filed 2024-03-06
$250.07M
derived: sum of 3 quarters · filed 2024-03-06
$302.99M
10-K · filed 2024-03-06
2021-09-30$60.24M
10-Q · filed 2022-11-08
$143.72M
derived: sum of 2 quarters · filed 2022-11-08
$196.65M
10-Q · filed 2022-11-08
$231.57M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30$83.47M
10-Q · filed 2022-08-09
$136.40M
10-Q · filed 2022-08-09
$171.32M
derived: sum of 3 quarters · filed 2022-08-09
$207.89M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31$52.93M
10-Q · filed 2022-05-10
$87.85M
derived: sum of 2 quarters · filed 2022-05-10
$124.41M
derived: sum of 3 quarters · filed 2022-05-10
$157.86M
derived: sum of 4 quarters · filed 2022-05-10
2020-12-31$34.92M
10-K · filed 2021-03-01
$71.49M
derived: sum of 2 quarters · filed 2021-11-09
$104.93M
derived: sum of 3 quarters · filed 2021-11-09
$131.49M
10-K · filed 2023-03-01
2020-09-30$36.57M
10-Q · filed 2021-11-09
$70.01M
derived: sum of 2 quarters · filed 2021-11-09
$96.57M
10-Q · filed 2021-11-09
$127.27M
derived: sum of 4 quarters · filed 2021-11-09
2020-06-30$33.45M
10-Q · filed 2021-08-09
$60.01M
10-Q · filed 2021-08-09
$90.71M
derived: sum of 3 quarters · filed 2021-08-09
$115.53M
derived: sum of 4 quarters · filed 2021-08-09
2020-03-31$26.56M
10-Q · filed 2021-05-10
$57.26M
derived: sum of 2 quarters · filed 2021-05-10
$82.08M
derived: sum of 3 quarters · filed 2021-05-10
$110.42M
derived: sum of 4 quarters · filed 2021-05-10
2019-12-31$30.70M
10-K · filed 2021-03-01
$55.52M
derived: sum of 2 quarters · filed 2021-03-01
$83.86M
derived: sum of 3 quarters · filed 2021-03-01
$115.22M
10-K · filed 2022-03-01
2019-09-30$24.82M
10-K · filed 2021-03-01
$53.16M
derived: sum of 2 quarters · filed 2021-03-01
$84.52M
10-Q · filed 2020-11-09
$116.52M
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$28.34M
10-K · filed 2021-03-01
$59.70M
10-Q · filed 2020-08-10
$91.70M
derived: sum of 3 quarters · filed 2021-03-01
$120.35M
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$31.36M
10-K · filed 2021-03-01
$63.37M
derived: sum of 2 quarters · filed 2021-03-01
$92.01M
derived: sum of 3 quarters · filed 2021-03-01
$121.66M
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$32.00M
10-K · filed 2020-03-12
$60.65M
derived: sum of 2 quarters · filed 2020-03-12
$90.30M
derived: sum of 3 quarters · filed 2020-03-12
$124.57M
10-K · filed 2021-03-01
2018-09-30$28.64M
10-K · filed 2020-03-12
$58.30M
derived: sum of 2 quarters · filed 2020-03-12
$92.57M
10-Q · filed 2019-11-12
$124.25M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30$29.65M
10-K · filed 2020-03-12
$63.93M
10-Q · filed 2019-08-08
$95.60M
derived: sum of 3 quarters · filed 2020-03-12
$127.43M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31$34.28M
10-K · filed 2020-03-12
$65.95M
derived: sum of 2 quarters · filed 2020-03-12
$97.78M
derived: sum of 3 quarters · filed 2020-03-12
$127.83M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31$31.68M
10-K · filed 2019-03-12
$63.51M
derived: sum of 2 quarters · filed 2019-03-12
$93.55M
derived: sum of 3 quarters · filed 2019-03-12
$125.86M
10-K · filed 2020-03-12
2017-09-30$31.83M
10-K · filed 2019-03-12
$61.88M
derived: sum of 2 quarters · filed 2019-03-12
$94.19M
10-Q · filed 2018-11-08
$125.07M
derived: sum of 4 quarters · filed 2019-03-12
2017-06-30$30.05M
10-K · filed 2019-03-12
$62.36M
10-Q · filed 2018-08-07
$93.24M
derived: sum of 3 quarters · filed 2019-03-12
$125.97M
derived: sum of 4 quarters · filed 2019-03-12
2017-03-31$32.31M
10-K · filed 2019-03-12
$63.19M
derived: sum of 2 quarters · filed 2019-03-12
$95.92M
derived: sum of 3 quarters · filed 2019-03-12
$120.35M
derived: sum of 4 quarters · filed 2019-03-12
2016-12-31$30.88M
10-K · filed 2018-03-14
$63.61M
derived: sum of 2 quarters · filed 2018-03-14
$88.04M
derived: sum of 3 quarters · filed 2018-03-14
$111.60M
10-K · filed 2019-03-12
2016-09-30$32.74M
10-K · filed 2018-03-14
$57.17M
derived: sum of 2 quarters · filed 2018-03-14
$80.73M
10-Q · filed 2017-11-08
$101.19M
derived: sum of 4 quarters · filed 2018-03-14
2016-06-30$24.43M
10-K · filed 2018-03-14
$47.99M
10-Q · filed 2017-08-08
$68.45M
derived: sum of 3 quarters · filed 2018-03-14
$88.91M
derived: sum of 4 quarters · filed 2018-03-14
2016-03-31$23.56M
10-K · filed 2018-03-14
$44.02M
derived: sum of 2 quarters · filed 2018-03-14
$64.48M
derived: sum of 3 quarters · filed 2018-03-14
$84.88M
derived: sum of 4 quarters · filed 2018-03-14
2015-12-31$20.46M
10-K · filed 2017-03-15
$40.91M
derived: sum of 2 quarters · filed 2017-03-15
$61.32M
derived: sum of 3 quarters · filed 2017-03-15
$74.86M
10-K · filed 2018-03-14
2015-09-30$20.45M
10-K · filed 2017-03-15
$40.86M
derived: sum of 2 quarters · filed 2017-03-15
$54.39M
10-Q · filed 2016-11-09
$67.86M
derived: sum of 4 quarters · filed 2017-03-15
2015-06-30$20.41M
10-K · filed 2017-03-15
$33.94M
10-Q · filed 2016-08-08
$47.41M
derived: sum of 3 quarters · filed 2017-03-15
$57.58M
derived: sum of 4 quarters · filed 2017-03-15
2015-03-31$13.53M
10-K · filed 2017-03-15
$27.00M
derived: sum of 2 quarters · filed 2017-03-15
$37.17M
derived: sum of 3 quarters · filed 2017-03-15
$51.13M
derived: sum of 4 quarters · filed 2017-03-15
2014-12-31$13.47M
10-K · filed 2016-03-14
$23.64M
derived: sum of 2 quarters · filed 2016-03-14
$37.60M
derived: sum of 3 quarters · filed 2016-03-14
$49.95M
10-K · filed 2017-03-15
2014-09-30$10.17M
10-K · filed 2016-03-14
$24.13M
derived: sum of 2 quarters · filed 2016-03-14
$36.48M
10-Q · filed 2015-11-09
$46.23M
derived: sum of 4 quarters · filed 2016-03-14
2014-06-30$13.95M
10-K · filed 2016-03-14
$26.31M
10-Q · filed 2015-08-10
$36.06M
derived: sum of 3 quarters · filed 2016-03-14
$44.78M
derived: sum of 4 quarters · filed 2016-03-14
2014-03-31$12.36M
10-K · filed 2016-03-14
$22.10M
derived: sum of 2 quarters · filed 2016-03-14
$30.82M
derived: sum of 3 quarters · filed 2016-03-14
$37.28M
derived: sum of 4 quarters · filed 2016-03-14
2013-12-31$9.74M
10-K · filed 2015-03-16
$18.46M
derived: sum of 2 quarters · filed 2015-03-16
$24.92M
derived: sum of 3 quarters · filed 2015-03-16
$33.01M
10-K · filed 2016-03-14
2013-09-30$8.72M
10-K · filed 2015-03-16
$15.18M
derived: sum of 2 quarters · filed 2015-03-16
$23.27M
10-Q · filed 2014-11-10
$30.63M
derived: sum of 4 quarters · filed 2015-03-16
2013-06-30$6.46M
10-K · filed 2015-03-16
$14.55M
10-Q · filed 2014-08-11
$21.91M
derived: sum of 3 quarters · filed 2015-03-16
$29.06M
derived: sum of 4 quarters · filed 2015-03-16
2013-03-31$8.09M
10-K · filed 2015-03-16
$15.45M
derived: sum of 2 quarters · filed 2015-03-16
$22.60M
derived: sum of 3 quarters · filed 2015-03-16
$29.82M
derived: sum of 4 quarters · filed 2015-03-16
2012-12-31$7.36M
10-K · filed 2014-03-17
$14.51M
derived: sum of 2 quarters · filed 2014-03-17
$21.73M
derived: sum of 3 quarters · filed 2014-03-17
$27.61M
10-K · filed 2015-03-16
2012-09-30$7.15M
10-K · filed 2014-03-17
$14.37M
derived: sum of 2 quarters · filed 2014-03-17
$20.25M
10-Q · filed 2013-11-12
$27.66M
derived: sum of 4 quarters · filed 2014-03-17
2012-06-30$7.22M
10-K · filed 2014-03-17
$13.10M
10-Q · filed 2013-08-09
$20.52M
derived: sum of 3 quarters · filed 2014-03-17
$29.49M
derived: sum of 4 quarters · filed 2014-03-17
2012-03-31$5.88M
10-K · filed 2014-03-17
$13.29M
derived: sum of 2 quarters · filed 2014-03-17
$22.27M
derived: sum of 3 quarters · filed 2014-03-17
$29.82M
derived: sum of 4 quarters · filed 2014-03-17
2011-12-31$7.41M
10-K · filed 2013-03-18
$16.39M
derived: sum of 2 quarters · filed 2013-03-18
$23.94M
derived: sum of 3 quarters · filed 2013-03-18
$31.43M
10-K · filed 2014-03-17
2011-09-30$8.97M
10-K · filed 2013-03-18
$16.53M
derived: sum of 2 quarters · filed 2013-03-18
$24.02M
10-Q · filed 2012-11-07
$31.66M
derived: sum of 4 quarters · filed 2013-03-18
2011-06-30$7.56M
10-K · filed 2013-03-18
$15.05M
10-Q · filed 2012-08-09
$22.69M
derived: sum of 3 quarters · filed 2013-03-18
$28.52M
derived: sum of 4 quarters · filed 2013-03-18
2011-03-31$7.49M
10-K · filed 2013-03-18
$15.13M
derived: sum of 2 quarters · filed 2013-03-18
$20.96M
derived: sum of 3 quarters · filed 2013-03-18
$27.08M
derived: sum of 4 quarters · filed 2013-03-18
2010-12-31$7.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18
$13.47M
derived: sum of 2 quarters · filed 2013-03-18
$19.58M
derived: sum of 3 quarters · filed 2013-03-18
$25.36M
10-K · filed 2013-03-18
2010-09-30$5.83M
10-Q · filed 2011-11-07
$11.94M
derived: sum of 2 quarters · filed 2011-11-07
$17.72M
10-Q · filed 2011-11-07
2010-06-30$6.11M
10-Q · filed 2011-08-05
$11.89M
10-Q · filed 2011-08-05
2009-12-31$23.08M
10-K · filed 2012-03-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
IMMUNIC, INC. (IMUX)United States$0.127B-1.88
Aardvark Therapeutics, Inc. (AARD)United States$0.121B-1.80
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
MEDICINOVA INC (MNOV)United States$0.130B-6.04
NRX Pharmaceuticals, Inc. (NRXP)United States$0.131B-6.31
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Unicycive Therapeutics, Inc. (UNCY)United States$0.134B-3.70
TuHURA Biosciences, Inc./NV (HURA)United States$0.134B-4.88
Immuneering Corp (IMRX)United States$0.113B-12.51